Strand strengthens team for programmable mRNA push
US mRNA-based therapeutics company Strand Therapeutics has announced the promotion of Prashant Nambiar (pictured above, left) to chief scientific officer and appointment of Ethan Cash (on right) as senior vice president, head of portfolio management and program development.
Dr Nambiar assumes his new role from his previous position as senior vice president in recognition of his ongoing leadership across Strand's discovery, preclinical, translational and computational biology teams.
He helped develop and continues to oversee Strand’s multidisciplinary research and nonclinical organization of more than 50 scientists, encompassing mRNA discovery and LNP delivery, synthetic and computational biology, pharmacology, automation, and preclinical safety.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze